1、June 23,2025|14:15 ETEli LillyLLY-NYSERatingOutperformPrice:Jun-20$762.73Target$900.00Total Rtn19%Is It Time to BELIEVE?-Bimagrumab Shows Robust Weight Loss in Combo Over SemaBottom Line:BELIEVE results move muscle preservation efforts forward with robust incremental weight loss over incretin therap

2、y.Bimagrumab+semaglutide treatment at 72 weeks led to a 22.1%reduction in body weight vs.15.7%for sema alone,a clear positive for building a regulatory approval case for body composition assets like bimagrumab.Questions around transient elevations in ALT/cholesterol and more permanent rises in lipas

3、es remain,but additional benefits in cardioprotective adiponectin,reductions in hsCRP,and HbA1c all contribute to a profile that could show clinical benefits beyond weight loss with additional data.Key PointsBimagrumab data shows additional weight loss in third muscle preservation readout in a month

4、.In a month packed with muscle preservation updates including data from Regenerons COURAGE trial and Scholar Rocks EMBRAZE,Lilly further extended this conversation presenting Ph 2 BELIEVE data of bimagrumab.BELIEVE data provides the most robust dataset to date for anti-ActRII targeting agents in com

5、bo with incretins and was able to show robust reductions in weight loss on top of semaglutide therapy.At 72 weeks,bimagrumab treatment with semaglutide led to a 22.1%reduction in body weight vs.15.7%seen by semaglutide at the same interval.To date,we have seen modest improvements in weight loss over

6、 incretin therapy from Regenerons trevogrumab and garetosmab(only additional 0.9%and 2.8%weight reduction from doublet and triplet therapy).However,previous results were only tested to 26 weeks.Scholar Rocks apitegromab combo therapy was unable to show incremental weight loss in EMBRAZE(1.1%less wei